Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. filings document a Nevada medical device issuer developing insulin delivery technology, including registration statements, material-event reports, shareholder approvals, and capital-structure changes. Disclosures cover common stock, warrants and pre-funded warrants, amendments to authorized shares, and the completed one-for-thirty reverse stock split.
MODD filings also record material agreements and financing arrangements, Nasdaq continued-listing matters, operating expense reductions, governance actions, risk-related disclosures, and securities registration information for the company’s Pivot-focused insulin pump business.
Modular Medical, Inc. (Nasdaq: MODD) has filed its Form 10-K for the fiscal year ended March 31, 2025. The filing confirms that the Nevada-incorporated diabetes-focused medical device company remains a non-accelerated filer, smaller reporting company, and is not an emerging growth company. The report was filed on a timely basis and the registrant affirms that all required reports and interactive data files have been submitted during the preceding 12 months.
Capital structure and market data: as of June 16, 2025, the company had 54,247,388 shares of common stock outstanding. The aggregate market value of shares held by non-affiliates was $62.27 million based on the September 30, 2024 Nasdaq closing price.
The 10-K outlines a full set of standard disclosures, including risk factors (Item 1A), management’s discussion & analysis (Item 7), and financial statements (Item 8), but detailed revenue, earnings and cash-flow figures are not included in the excerpt provided. A lengthy Special Note Regarding Forward-Looking Statements lists more than a dozen risk considerations, mainly centred on:
- Obtaining FDA clearances for its insulin pump products.
- Financing needs and liquidity horizon.
- Competition from larger diabetes device manufacturers.
- Protection of intellectual property.
- Ability to hire and retain key personnel.
The company confirms it is not a shell company and that no restatement-triggering error corrections were included in the financials. No attestations under SOX 404(b) were provided, consistent with non-accelerated filer status.
Overall, the filing is largely procedural and centres on forward-looking risk disclosures rather than new financial performance metrics or strategic transactions.